Q Li1, S Wu2, J Zhou3, J Sun1, F Li1, Q Lin2, X Guan1, H Lin1, Z He1. 1. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine, Guangzhou, PR China. 2. Xiamen Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, PR China. 3. Xiamen Cancer Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen, PR China.
Abstract
BACKGROUND: We investigated risk factors for locoregional recurrence (lrr) in breast cancer patients with 4 or more positive axillary lymph nodes receiving postmastectomy radiotherapy (pmrt). METHODS: Medical records (1998-2007) were retrospectively reviewed for the population of interest. The Kaplan-Meier method was used to calculate the survival rate; Cox regression models were used for univariate and multivariate analysis of predictors of breast cancer lrr. RESULTS: The study enrolled 439 patients. Median duration of follow-up was 54 months. The 5-year rates of locoregional recurrence-free survival (lrrfs), distant metastasis-free survival (dmfs), and breast cancer-specific survival (bcss) were 87.8%, 59.5%, and 70.7% respectively. In patients with lrr and no concomitant metastasis, and in those without lrr, the 5-year rates of dmfs were 21.1% and 65.7% respectively (p < 0.001), and the 5-year rates of bcss were 34.5% and 76.4% respectively (p < 0.001). Univariate analysis showed that menopausal status (p = 0.041), pN stage (p = 0.006), and positivity for her2 [human epidermal growth factor receptor 2 (p = 0.003)] or the triple-negative disease subtype (p < 0.001) were determinants of lrrfs. Multivariate analysis showed that pN3 stage [hazard ratio (hr): 2.241; 95% confidence interval (ci): 1.270 to 3.957; p = 0.005], her2 positivity (hr: 2.705; 95% ci: 1.371 to 5.335; p = 0.004), and triple-negative disease subtype (hr: 4.617; 95% ci: 2.192 to 9.723; p < 0.001) were independent prognostic factors of lrrfs. CONCLUSIONS: In breast cancer patients with 4 or more positive axillary lymph nodes who undergo pmrt for breast cancer, lrr significantly influences survival. Patients who developed lrr carried a high risk for distant metastasis and death. Pathologic stage (pN3), her2 positivity, and the triple-negative disease subtype are risk factors that significantly influence lrrfs.
BACKGROUND: We investigated risk factors for locoregional recurrence (lrr) in breast cancerpatients with 4 or more positive axillary lymph nodes receiving postmastectomy radiotherapy (pmrt). METHODS: Medical records (1998-2007) were retrospectively reviewed for the population of interest. The Kaplan-Meier method was used to calculate the survival rate; Cox regression models were used for univariate and multivariate analysis of predictors of breast cancer lrr. RESULTS: The study enrolled 439 patients. Median duration of follow-up was 54 months. The 5-year rates of locoregional recurrence-free survival (lrrfs), distant metastasis-free survival (dmfs), and breast cancer-specific survival (bcss) were 87.8%, 59.5%, and 70.7% respectively. In patients with lrr and no concomitant metastasis, and in those without lrr, the 5-year rates of dmfs were 21.1% and 65.7% respectively (p < 0.001), and the 5-year rates of bcss were 34.5% and 76.4% respectively (p < 0.001). Univariate analysis showed that menopausal status (p = 0.041), pN stage (p = 0.006), and positivity for her2 [humanepidermal growth factor receptor 2 (p = 0.003)] or the triple-negative disease subtype (p < 0.001) were determinants of lrrfs. Multivariate analysis showed that pN3 stage [hazard ratio (hr): 2.241; 95% confidence interval (ci): 1.270 to 3.957; p = 0.005], her2 positivity (hr: 2.705; 95% ci: 1.371 to 5.335; p = 0.004), and triple-negative disease subtype (hr: 4.617; 95% ci: 2.192 to 9.723; p < 0.001) were independent prognostic factors of lrrfs. CONCLUSIONS: In breast cancerpatients with 4 or more positive axillary lymph nodes who undergo pmrt for breast cancer, lrr significantly influences survival. Patients who developed lrr carried a high risk for distant metastasis and death. Pathologic stage (pN3), her2 positivity, and the triple-negative disease subtype are risk factors that significantly influence lrrfs.
Entities:
Keywords:
Breast cancer; locoregional recurrence; mastectomy; prognostic analysis; radiotherapy
Authors: Ana P Kiess; Heather L McArthur; Kathleen Mahoney; Sujata Patil; Patrick G Morris; Alice Ho; Clifford A Hudis; Beryl McCormick Journal: Cancer Date: 2011-09-01 Impact factor: 6.860
Authors: Janet K Horton; Jan Halle; Madlyn Ferraro; Lisa Carey; Dominic T Moore; David Ollila; Carolyn I Sartor Journal: Int J Radiat Oncol Biol Phys Date: 2009-06-27 Impact factor: 7.038
Authors: Jun Sang Lee; Seung Il Kim; So Young Choi; Hyung Seok Park; Jong Seok Lee; Seho Park; Jaseung Koo; Byeong-Woo Park; Kyong Sik Lee Journal: Int J Clin Oncol Date: 2011-03-01 Impact factor: 3.402
Authors: M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: Daniel T Chang; Steven J Feigenberg; Daniel J Indelicato; Christopher G Morris; Judith Lightsey; Stephen R Grobmyer; Edward M Copeland; Nancy P Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-15 Impact factor: 7.038
Authors: J E Panoff; J Hurley; C Takita; I M Reis; W Zhao; V Sujoy; C R Gomez; M Jorda; L Koniaris; J L Wright Journal: Breast Cancer Res Treat Date: 2011-04-08 Impact factor: 4.872
Authors: Stanley K Liu; Carla Coackley; Mechthild Krause; Farid Jalali; Norman Chan; Robert G Bristow Journal: Radiother Oncol Date: 2008-05-02 Impact factor: 6.280
Authors: Isabelle Gingras; Eileen Holmes; Evandro De Azambuja; David H A Nguyen; Miguel Izquierdo; Jo Anne Zujewski; Moshe Inbar; Bjorn Naume; Gianluca Tomasello; Julie R Gralow; Antonio C Wolff; Lyndsay Harris; Michael Gnant; Alvaro Moreno-Aspitia; Martine J Piccart; Hatem A Azim Journal: J Natl Cancer Inst Date: 2017-08-01 Impact factor: 13.506